Observation And Study On Efficacy And Safety Of Biologics In The Treatment Of Psoriasis

Objective: To review the clinical features of skin conditions characterized by itching in patients with psoriasis treated with biologics and to explore the possible pathogenesis.To evaluate the efficacy and safety of guselkumab in the treatment of moderate to severe plaque psoriasis.Methods: Retrospective analysis was performed on patients with psoriasis who had been treated with biologics from June 2019 to November2020,SPSS 22.0 software was used for statistical analysis,the clinical characteristics were explored.All literatures on the treatment of moderate to severe plaque psoriasis with Guselkumab were retrieved.Two researchers screened the literature,evaluated the quality of the literatures and extracted the data strictly according to the inclusion and exclusion criteria.Revman5.3 software was used for Meta analysis.Results: A total of 92 patients were Included,of whom 20(21.7%)occurred skin conditions characterized by itching.Psoriasis Area and Severity Index score and itching degree were negatively correlated with the occurrence of skin conditions characterized by itching.According to the inclusion and exclusion criteria,five articles were included,2049 patients were enrolled.In terms of efficacy,the number of patients with psoriatic lesion improvement indexes(PASI75,PASI90,PASI100,IGA0/1,DLQI0/1)in guselkumab group was significantly higher than that in placebo group and adalimumab group(P < 0.01).In terms of safety,there was no significant difference in adverse reactions between the guselkumab group and the placebo group(P > 0.05).Conclusion: The incidence of skin conditions characterized by itching was high,and it was negatively correlated with PASI score and pruritus degree before treatment.The short-term efficacy of guselkumab in the treatment of moderate to severe psoriasis is positive and superior to that of adalimumab,and there is no significant difference in safety between guselkumab and placebo.